Antilymphoma Treatments Given Subsequent to Yttrium 90 Ibritumomab Tiuxetan Are Feasible in Patients with Progressive Non-Hodgkin's Lymphoma: A Review of the Literature
- 1 December 2004
- journal article
- review article
- Published by Elsevier in Clinical Lymphoma
- Vol. 5 (3) , 202-204
- https://doi.org/10.3816/clm.2004.n.028
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2003
- Subsequent Chemotherapy Regimens Are Well Tolerated After Radioimmunotherapy With Yttrium-90 Ibritumomab Tiuxetan for Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2002
- Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2002
- Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trialBlood, 2002
- Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2002